Fabry disease is caused by
an inherited x-linked deficiency of the α-Galactosidase A (GLA) gene. GLA deficiency leads to systemic intracellular accumulation of the glycosphingolipid globotriaosylceramide (Gb3), mainly in
heart, brain and kidney. Podocyte injury du to progressive Gb3 accumulation is the major cause for albuminuria, chronic kidney disease and kidney failure in patients with Fabry disease. To
elucidate specific disease mechanisms in GLA deficiency we generated GLA knockouts in mouse, rat, fly and cultured podocytes followed by deep phenotyping and extensive omics analysis of these
in-vivo and ex-vivo models. Our future work is focused to open new avenues for translational and precision medicine to ultimately prevent kidney failure in Fabry disease.
group aims to discover novel pathomechanisms in Fabry's disease through the establishment of a Fabry stem cell biobank. This will enable us to investigate mutation- and cell type-specific effects
of alpha-Galactosidase A impairment and Gb3 accumulation in various cell types and in vitro systems differentiated from Fabry stem cells.